メニュー 戻る[Session 3]Cardiovascular risk assessment of antitumor drugs

8th DIA Cardiac Safety Workshop in Japan


[Session 3]Cardiovascular risk assessment of antitumor drugs

Session Chair(s)

Keita  Fujikawa

Keita Fujikawa

  • Head of General Medicine, Japan Medical Office
  • Takeda Pharmaceutical Company Limited, Japan
Yuji  Kumagai, MD, PhD

Yuji Kumagai, MD, PhD

  • Professor, Clinical Research Center
  • Kitasato University Hospital, Japan

Speaker(s)

Tadahiro  Shinozawa, PhD

Safety translational research for cardio-oncology using iPS cells

Tadahiro Shinozawa, PhD

  • Associate Director, Drug Safety Research Lab, Regenerative Medicine Unit
  • Takeda Pharmaceutical Company Limited, Japan
Yoshito  Zamami

Development of preventive treatment against anticancer drug-induced side effects using big data analysis

Yoshito Zamami

  • Associate professor, Department of Clinical Pharmacology and Therapeutics,
  • Tokushima University Graduate School, Japan
Hideaki  Takahashi

Cardiovascular risk assessment of antitumor drugs

Hideaki Takahashi

  • Reviewer
  • Pharmacheuticals and Medical Devices Agency, Japan

お問い合わせ

Please contact DIA Japan for further information.

Send Email
+81.3.6214.0574